Drug Trial Radar · NCT02203149
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Aug 1, 2014
Primary completion
Oct 2, 2015
Study completion May 16, 2016
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1). Part I is a dose-finding study; in Part II, participants will be randomly assigned to receive grazoprevir at the dose determined in Part I in combination with elbasvir. The primary study hypothesis is that the percentage of treatment-naïve participants in the Immediate Treatment Arm of Part II who achieve sustained viral response at 12 weeks after the end of all treatment (SVR12) will be greater than the reference rate of 75%. A separate study arm for cirrhotic participants will also be included in Part II; these participants will receive grazoprevir at the determined dose in combination with elbasvir.
Conditions
- Hepatitis C
Interventions
GrazoprevirDrug
One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
ElbasvirDrug
One 50 mg tablet taken orally once daily for 12 weeks.
Placebo to GrazoprevirDrug
One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
Placebo to ElbasvirDrug
One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 2: Percentage of Treatment-naïve Participants in the Immediate Treatment Arm Achieving Sustained Viral Response at 12 Weeks After The End of All Treatment (SVR12)Time frame: 12 weeks after end of all therapy in Part 2 (Study Week 24 of Part 2)
- Part 1: Percentage of Participants Experiencing an Adverse Event (AE) During Treatment and First 4 Follow-Up WeeksTime frame: Up to 4 weeks post last dose in Part 1 (Up to total of 16 weeks)
- Part 1: Percentage of Participants That Discontinued Treatment Due to an AETime frame: Up to Study Week 12 in Part 1
- Part 2: Percentage of Participants Experiencing an AE During Initial Treatment and First 4 Follow-Up WeeksTime frame: Up to 4 weeks following initial treatment in Part 2 (Up to total of 16 weeks)
- Part 2: Percentage of Participants That Discontinued Initial Treatment Due to an AETime frame: Up to Study Week 12 in Part 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.